Please login to the form below

Not currently logged in
Email:
Password:

Teva takes majority stake in Taiyo

Israel's Teva is to take 57 per cent share in Japanese generic medicines manufacturer Taiyo

Teva Pharmaceutical Industries has signed a definite agreement to acquire 57 per cent of the share held in privately-owned Taiyo Pharmaceutical Industry Company for $460m in cash.

Shlomo Yanai, Teva president and chief executive, said: "This acquisition will enable Teva to deliver on our strategic objective of becoming a leading player in the fast-growing Japanese generics market. In fact, we now expect to reach our 2015 target of $1bn sales in Japan ahead of schedule."

The deal is subject to the approval of Taiyo's shareholder meeting, but it is expected to be complete by the end of September.

Meanwhile Teva has won the largest share of a new drug delivery tender by Germany's largest healthcare fund Allgemeinen Orstskrankassen. It secured 152 two-year supply contracts, 27 per cent of the contracts in the tender. The contracts come into effect on June 1.

16th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics